PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018).
Loading...
Embargo End Date
Authors
Syndikus, I
Cruickshank, C
Staffurth, J
Tree, A
Henry, A
Naismith, O
Mayles, H
Snelson, N
Hassan, S
Brown, S
Porta, N
Griffin, C
Hall, E
Cruickshank, C
Staffurth, J
Tree, A
Henry, A
Naismith, O
Mayles, H
Snelson, N
Hassan, S
Brown, S
Porta, N
Griffin, C
Hall, E
Document Type
Journal Article
Date
2020-11-01
Date Accepted
2020-08-24
Abstract
•PIVOTALboost evaluates benefits/toxicity of pelvic node RT and focal boost dose escalation.•Unfavourable intermediate/high risk and bulky local disease are most likely to benefit.•Functional MRI imaging is used to select patients for different types of dose escalation.•HDR brachytherapy or focal dose escalation with IMRT are used as options.•Training and support is provided to reduce variations of contouring and radiotherapy planning.•The trial is recruiting patients in 38 radiotherapy centres through the UK.
Citation
Clinical and translational radiation oncology, 2020, 25 pp. 22 - 28
Source Title
Publisher
ELSEVIER IRELAND LTD
ISSN
2405-6308
eISSN
2405-6308
Collections
Research Team
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
ICR-CTSU Urology and Head and Neck Trials Team